NeonMind Biosciences Inc. is pleased to announce that Vitasave has agreed to carry all four of NeonMind's functional mushroom infused coffees through Vitasave's eCommerce platform.
Vancouver, British Columbia (Newsfile Corp. - May 28, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FFE: 6UF) ("NeonMind"), an integrated drug development and wellness company focused
FFE: 6UF) (“
NeonMind“), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, is pleased to announce that its shares will commence trading on the OTCQB® Venture Market (the “
OTCQB“) on May 28, 2021, under the symbol “NMDBF”.
We apologize, but this video has failed to load.
Try refreshing your browser.
To view an enhanced version of this graphic, please visit:
The OTCQB, operated by OTC Markets Group Inc., is designed for early-stage and developing U.S. and international companies. Companies must be current in their financial reporting and undergo an annual verification and management certification process, including meeting a minimum bid price and other financial conditions. With more compliance and quality standards, the OTCQB provides investors improved visibility to enhance trading decisions. The OTCQB is recognized by the United States Securities and
NeonMind Biosciences Inc: NeonMind Announces Creation of Medical Clinics Advisory Board to Guide Planning and Operation of Company-Branded Clinics Across Canada
NeonMind Biosciences Inc. (
FSE: 6UF) (
NeonMind ), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, is pleased to announce the formation of a Medical Clinic Advisory Board to guide the planning and operation of NeonMind branded clinics across Canada. Members of the advisory board will be comprised of experts on provincial and local health care access and advocacy, ketamine treatment and psychotherapy protocols, and clinical operations, strategy, and growth.